EGFR and glioblastoma: Last, the HELDR-KAT7 axis facilitates the expression of genes associated with GBM resistance to EGFR inhibitors (EGFRi) and targeting KAT7 or HELDR significantly enhances GBM responses to EGFRi treatments in vivo.